Metagenomi Therapeutics (MGX) Equity Average (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Equity Average data on file, last reported at $148.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at $148.2 million, down 33.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $148.2 million (down 33.77% YoY), and the FY2025 annual result was $196.7 million, up 296.33% from the prior year.
• Equity Average slipped to $148.2 million in Q1 2026 per MGX's latest filing, from $168.5 million in the prior quarter.
• Over five years, Equity Average peaked at $272.5 million in Q2 2024 and troughed at -$96.3 million in Q2 2023.
• A 4-year average of $130.6 million and a median of $177.8 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2026: Equity Average surged 611.59% in 2024, then tumbled 33.77% in 2026.
• A 4-year view of Equity Average shows it stood at -$67.9 million in 2023, then jumped by 461.55% to $245.3 million in 2024, then slumped by 31.3% to $168.5 million in 2025, then decreased by 12.06% to $148.2 million in 2026.
• Business Quant data shows MGX's Equity Average at $148.2 million in Q1 2026, $168.5 million in Q4 2025, and $187.1 million in Q3 2025.